A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53
Tuesday, September 8, 2015 poster session. Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Tuesday, September 8, 2015 poster session. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma
Monday, June 1, 2015 poster session. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma Multiforme (GBM)
Monday, April 20, 2015 poster session: VAL-083 Phase 1/2 data poster # CT217: Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma
Monday, April 20, 2015 poster session: VAL-083 GBM preclinical poster #2562: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo
Sunday, April 19, 2015 poster session: VAL-083 NSCLC preclinical poster # 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer
